AA 2007 Bifurcation PCI and UK Trial Update Rosie Swallow Royal Bournemouth Hospital.

Slides:



Advertisements
Similar presentations
ENDEAVOR IV Acronym: ENDEAVOR IV. Lead investigator: Dr Martin Leon from Columbia University, New York Source: Transcatheter cardiovascular Therapeutics,
Advertisements

A Prospective, Randomized Comparison of Paclitaxel-eluting TAXUS Stents vs. Bare Metal Stents During Primary Angioplasty in Acute Myocardial Infarction.
B alloon-pump assisted C oronary I ntervention S tudy BCIS-1 Simon Redwood Kings College London/ St Thomas Hospital Steering Committee: Divaka Perera,
“Real World”: SVG, De Novo or Restenotic Coronary Artery Lesions Chronic Stable Angina, Silent Ischemia, Acute Coronary Syndromes Vessel Diameters:
BCIS Returns 1998 (Oct 1999) BCIS Audit Returns of Interventional Procedures 1998 Leicester, October 1999 Mark de Belder (Audit Secretary, BCIS) on behalf.
BCIS Audit Returns of Interventional Procedures 2000 Mark de Belder BCIS UK National Audit Officer on behalf of Council of the British Cardiovascular Intervention.
BBC ONE David Hildick-Smith Sussex Cardiac Centre Brighton, UK on behalf of the BBC ONE Investigators.
BIFURCATION LESIONS Dr. Tahsin.N
Distal Protection: PRIDE, CAPTIVE Symbiot III, AiMI Dr James Cotton MD MRCP Heart and Lung Centre Wolverhampton.
ARTS I & II Keith D Dawkins Southampton University Hospital.
Multivessel coronary disease diagnosed at the time of primary PCI for STEMI: complete revascularization versus conservative strategy. PRAGUE 13 trial O.
STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients Bruce Brodie, Adam Bensimhon, Nathan Fleishman, Charles Hansen, Mike Cooper,
PCI VS CABG JOURNAL REVIEW
Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)
DIABETES trial P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín, J Goicolea, F Alfonso, C Bañuelos, J Escaned, R Moreno,
Clinical Result Overview
Coronary Artery Revascularisation
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
UK Trial Update Simon Redwood Advanced Angioplasty Jan 2006 No Conflict of Interest.
TITAX AMI Trial Y. Giraud-Sauveur on behalf of P.Karjalainen, MD, PhD : Principal Investigator BCIS 2009 London, UK A Prospective, Randomized Trial Comparing.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
B alloon-pump assisted C oronary I ntervention S tudy BCIS-1 Simon Redwood St Thomas’ Hospital / King’s College London On behalf of the BCIS-1 Investigators.
RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.
Richard Melsheimer Director, Medical Affairs Europe Centocor Eli Lilly and Company Coordinated Use of ReoPro and Drug Eluting Stents: Rationale and Evidence.
Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.
FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary.
David Hildick-Smith Sussex Cardiac Centre. Background to ARTS Previous POBA studies Meta-analysis 3300 patients 1660 CABG, 1710 PTCA Deaths 79 PCI vs.
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
Side Branch Stenting Using Sirolimus-Eluting Stents in Bifurcation Lesions Trial Presented at The American College of Cardiology Scientific Session 2006.
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
Treatment of bifurcation lesions is a complex problem Different techniques are commonly used (Y-/T-stenting, „culotte“ technique, „kissing stent“ technique…)
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
Balloon-pump assisted Coronary Intervention Study BCIS-1 Simon Redwood Divaka Perera, Rod Stables, Martyn Thomas.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
RAVEL 4 YEAR FOLLOW-UP - Cordis Cardiology / Cardialysis – Euro-PCR – Sousa – 24 May 2005 RAVEL A RAndomised, double-blind study with the Sirolimus-eluting.
End points in PTCA trials. A successful angioplasty is defined as the reduction of a minimum stenosis diameter to
Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
Disclosures Runlin Gao has received a research grant
Runlin Gao, M.D. On behalf of ABSORB China Investigators
Final Five-Year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients With Three-Vessel Disease and/or Left Main Disease Patrick.
Simon Redwood Advanced Angioplasty Jan 2006
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
On behalf of J. Belardi, M. Leon, L. Mauri,
Balloon-pump assisted Coronary Intervention Study (BCIS-1):
FINAL FIVE-YEAR CLINICAL OUTCOMES OF THE NOBORI2 TRIAL
Stenting of Coronary Arteries in Non Stress/Benestent Disease
Two-Year Extended Follow-up in Patients Receiving a Zotarolimus-eluting Stent in the E-Five Registry Martin T. Rothman, Ian T. Meredith, Keyur Parikh,
American College of Cardiology Presented by Dr. Stephan Windecker
Incidence And Management Of Restenosis After Treatment Of Unprotected Left Main Disease With Drug-Eluting Stents: 70 Restenotic Cases From A Cohort Of.
Giuseppe Biondi Zoccai, MD
3-Year Clinical Outcomes From the RESOLUTE US Study
The American College of Cardiology Presented by Dr. Raimund Erbel
Large-Scale Registry Examining Safety and Effectiveness of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Western.
American Heart Association Presented by Dr. Julinda Mehilli
Impact of Platelet Reactivity Following Clopidogrel Administration
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
SORT-OUT III: A Prospective Randomized Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Michael.
Presented at TCT 2006.
Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Jeffrey J
Maintenance of Long-Term Clinical Benefit with
DEScover: One-Year Clinical Results
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Ahmed A. Khattab, MD For the German Cypher Registry Investigators
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
Atlantic Cardiovascular Patient Outcomes Research Team
The American College of Cardiology Presented by Dr. A. Abazid
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Presentation transcript:

AA 2007 Bifurcation PCI and UK Trial Update Rosie Swallow Royal Bournemouth Hospital

AA 2007 No conflicts of interest

AA 2007 Randomized Study on Simple Versus Complex Stenting of Coronary Artery Bifurcation Lesions. The Nordic Bifurcation Study Circulation. 2006;114:

AA 2007 Background Optimal stenting strategy in coronary artery bifurcation lesions is unknown Sirolimus coated stents reduce the rate of restenosis in simple and complex coronary artery lesions

AA 2007 Nordic Bifurcation Study Non blinded Randomised Multi-centre 28 cardiology centres – Denmark, Sweden, Finland, Norway and Latvia September 2004 – May 2005

AA 2007 Aim Compare two stenting strategies in de novo bifurcation lesions using Sirolimus Eluting Stents (SES): I.Stenting Main Vessel and optional stenting of side branch (MV) II.Stenting Main Vessel and Side Branch (MV+SB)

AA 2007 Randomised patients (n:413) Stenting main vessel only (MV) (n: 207) Stenting main vessel and side branch (MV+SB) (n: 206) Clinical Follow up, 6 months (n: 207) Clinical Follow up, 6 months (n: 206) Scheduled angiographic Follow up after 8 months (n: 176) Scheduled angiographic Follow up after 8 months (n: 182) Angiographic Follow up available (n: 151) Angiographic Follow up available (n: 156)

AA 2007 Inclusion criteria Stable or unstable AP or silent ischemia Bifurcation lesion (including LMS in RCA dominant) Diameter of main vessel by visual estimate ≥2.5 mm Diameter of side branch by visual estimate ≥2.0 mm

AA 2007 Exclusion criteria ST- elevation AMI within 24 hours Expected survival <1year Serum creatinine >200 μmol/l Allergy to aspirin, clopidogrel or ticlopidine Allergy to sirolimus Left main bifurcation in a non-right dominant system

AA 2007 Primary end points Combined end point at 6 months of : Cardiac death Myocardial infarction Stent thrombosis Target vessel revascularisation

AA 2007 Secondary end points Combined end point of cardiac death, index lesion MI, target lesion revascularization (TLR), stent thrombosis Procedure related biomarker increase Angiographic follow-up after 8 months

AA 2007

QCA Analysis at 8/ patientsMVMV+SBp (n:151)(n:156) MLD SB (mm)1.52 ± ±0.60<0.001 late lumen loss SB (mm)-0.04 ± ± 0.57<0.001 Restenosis MV (%) Restenosis SB(%)

AA 2007 Study Limitations Open design No ischaemia testing Underpowered given low MACE rate Variety of lesion types and locations Clinical follow up at 6/12 Angiography at 8/12 Long term results not known

AA 2007 Conclusions Excellent 6/12 clinical and 8/12 angiographic results Procedural success rates high, MACE low, angiographic restenosis low, independent of stenting strategy Reduced procedure and fluoroscopy times, reduced contrast and reduced risk of biomarker elevation in simple strategy Simple strategy recommended as routine for bifurcations

AA 2007 Balloon-pump assisted Coronary Intervention Study ( BCIS-1) Study Update A British Cardiovascular Intervention Society Project Funded by Datascope, Cordis and Lilly

AA 2007 Study Design Prospective, open, multi centre, randomised trial Randomisation to Elective IABP or No Planned IABP Sample size 300 Follow-up to hospital discharge or 28 days after randomisation Six month follow-up ONS / GROS

AA 2007 Main Eligibility Criteria - Inclusion Proposed single or multi-vessel PCI Presence of both the following 1.EF<30% 2.Large area of myocardium at risk (one of the following) –Unprotected LMS target lesion –Jeopardy score ≥8 –Target vessel provides collateral supply to an occluded 2 nd vessel which supplies > 40% myocardium

AA 2007 Main Eligibility Criteria - Exclusion Systolic BP<85mmHg despite correction of hypovolaemia Acute MI within previous 48 hours Planned staged PCI within 28 days of index PCI CI to IABP

AA 2007 Outcomes Primary Outcome MACE at hospital discharge or 28 days Secondary Outcomes Mortality at 6/12 Procedural complications Bleeding complications Access site complications

AA 2007 InstitutionPrincipal InvestigatorStudy Co-ordinator Birmingham HeartlandsDr Mike PittJuliet Hulse Glenfield HospitalDr Anthony GershlickAmanda Lloyd Kings College LondonDr Martyn ThomasJoanne Gregory Manchester Heart CentreDr Doug FraserHeather Iles-Smith Liverpool CTCDr Rod StablesHeather Rodgers Royal Victoria HospitalDr David RobertsLesley Radford Royal Sussex County HospitalDr Adam de BelderNina Cooter Royal Bournemouth GeneralDr Rosie SwallowNicki Lakeman St George'sDr Stephen BreckerSue Brown St Thomas HospitalDr James CouttsAlison Child University Hospital of North StaffordshireDr Jim NolanJulie Machin Wessex CTCDr Nick CurzenZoe Nicholas Western InfirmaryDr Keith OldroydJoanne Kelly Wythenshaw HospitalDr Bernard PrendegastTeresa Coppenger Wolverhampton Heart & Lung CentreDr James CottonAndy Smallwood Yorkshire Heart CentreDr Dan BlackmanClaire Priestley

AA 2007 BCIS-1 Study Recruitment at 19 th January 2006 Total 88 patients

AA 2007 Average recruitment per site last 4 months is 0.7pts/month BCIS-1 Projected Study Recruitment End Sep 2008End Feb 2008

AA 2007 Study Timelines MREC submission24 th Mar 2005 MREC approval28 th Apr st REC approval13 th May 2005 First patient20 th Dec 2005 New target of 25 – 30 centres Invite more centresJan/Feb 2007 Projected end recruitmentFeb/Mar 2008

AA 2007 Join BCIS-1Centres - Contacts Rod Simon Redwood Divaka Jean

AA 2007 BBC ONE The B ritish B ifurcation C oronary study: O ld, N ew and E volving strategies A randomised comparison of simple versus complex drug-eluting stenting for bifurcation lesions

AA 2007 BBC ONE Inclusion criteria >18 yrs Stable or unstable angina Bifurcation types I-IV suitable for stenting of both vessels Vessel diameters ≥ 2.25mm side, ≥ 2.5mm main

AA 2007 BBC ONE Simple – provisional T-stenting Following main vessel stenting, the side branch should not be treated further unless there is: <TIMI 3 flow in the side branch Severe ostial pinching (>90%) of the side branch Threatened side vessel closure Side-branch dissection >type A Complex – crush or culotte

AA 2007 BBC ONE Primary endpoints (9 months) Death Target vessel failure –main vessel or side branch TIMI<3 (after vasodilators) on further angiogram –main vessel or side branch undergoes attempted repeat PCI/CABG Myocardial infarction

AA 2007 BBC ONE January 1 st 2007 Steering committee: David Hildick-Smith Rod Stables Nick Curzen Keith Oldroyd No. Patients recruited 310 RECRUITING CENTRES CENTREINVESTIGATORADMINISTRATORRECRUITMENT BrightonHildick-SmithCooter82 WolverhamptonCottonSmallwood27 CoventryGlennonGill26 BristolBaumbachSingh25 Kings CollegeThomasGregory23 LiverpoolStablesMatata22 Dublin (St. James)MulvihillWalsh17 GlasgowOldroydKelly15 SouthamptonCurzenKitt15 NottinghamHendersonBurton11 St George ’ sBreckerBrown11 BournemouthTalwarLakeman11 London (St. Thomas)RedwoodEvans8 Dublin (Beaumont)FoleyMcGrath6 StokeButlerMachin3 ManchesterFaz-OrdoubadiGray2 BirminghamLudmanBlount1 ReadingOrrTurner1 EdinburghStarkeyOsborne1 Birmingham (West)Varma 1

AA 2007 BBC ONE recruitment to January 1 st 2007 (Ethics-approved centres)

AA 2007 BBC ONE current and target recruitment January 1 st 2007

AA 2007 Study Timelines Regulatory Approval (COREC/MHRA) Nov 2004 Pilot Study (Brighton Site Only) Jan 2005 First Wave of UK Sites recruiting Nov st Interim analysis (220 pts) Sep nd Interim analysis (350 pts) Final patient recruited July 2007 Follow up complete Mar 2008 Presentation May 2008

AA 2007 BBC 1 Contacts David Hildick Smith Nina Cooter

AA 2007 The CARDia Trial C oronary A rtery R evascularisation in Dia betes

AA 2007 Multi-centre, randomised, prospective comparison of PCI vs CABG for diabetics with MV or complex SVD ‘Up-to-date’ strategy – DES, GPIIbIIIa, Arterial conduits, off- pump, optimum glucose control Non Inferiority design, target 600 patients, revised to 500 Dec 2006 Study Design

AA 2007 Diabetic patients with multivessel disease or complex single vessel disease Suitable for PCI or CABG Inclusion and exclusion criteria met CONSENT Randomisation CABGPCI +DES No registry No registry No registry

AA 2007 Primary endpoint: Composite event rate at 1 year of death/non-fatal MI/non-fatal stroke Major secondary endpoint: Further revascularisation procedures Follow up is at 30 days, 6 months, 1 year, 2 years

AA 2007 CARDia Centres The 8 centres London are: Hammersmith St Mary’s St Thomas’ Kings College London Chest Harefield St Bart’s Royal Brompton Hairmyers Glasgow Western James Cook University Dublin Brighton Southampton Papworth LONDON Bristol Birmingham Nottingham Blackpool LiverpoolSheffield Manchester Stoke

AA 2007 Recruitment

AA 2007 Study Timelines MREC approval was granted August 2001 First sites activated January 2002 Plan to finish recruitmentApril 2007 Application for additional funding to support follow up at 5 years.

AA 2007 CARDia Contacts Co-chief Investigator and Chairman of Steering Committee - Prof Roger Hall (Norfolk and Norwich and Hammersmith Hospitals) Co-chief investigator and Project Manager - Dr Akhil Kapur (London Chest Hospital) Director CTEU - Dr Marcus Flather (Royal Brompton Hospital) Study co-ordinator - Nicola Delahunty (CTEU, Royal Brompton Hospital) Study has been managed by CTEU at the Royal Brompton Hospital since April Prior to this time it was managed at the Hammersmith Hospital.